Drug Profile
CP 95253
Latest Information Update: 07 May 2003
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Gastric inhibitory polypeptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 07 May 2003 Discontinued - Phase-I for Diabetes mellitus in USA (unspecified route)
- 01 Apr 1997 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
- 12 Nov 1993 Phase-I clinical trials for Diabetes mellitus in USA (Unknown route)